As filed with the Securities and Exchange Commission on March 10, 2022
Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CULLINAN ONCOLOGY, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware |
|
81-387991 |
(State or Other Jurisdiction of Incorporation or Organization) |
|
(I.R.S. Employer Identification No.) |
|
|
One Main Street
Suite 520 Cambridge,
MA |
|
02142 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Cullinan Oncology, Inc. (formerly Cullinan Management, Inc.) 2021 Stock Option and Incentive Plan
Cullinan Oncology, Inc. (formerly Cullinan Management, Inc.) 2021 Employee Stock Purchase Plan
(Full Title of the Plan)
Nadim Ahmed
President
and Chief Executive Officer
Cullinan Oncology, Inc.
One Main Street
Suite
520
Cambridge, MA 02142
(Name and Address of Agent For Service)
(617) 410-4650
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐